Literature DB >> 20842049

Comparison of two automatic methods for the assessment of brachial artery flow-mediated dilation.

Francesco Faita1, Stefano Masi, Stavros Loukogeorgakis, Vincenzo Gemignani, Mike Okorie, Elisabetta Bianchini, Marietta Charakida, Marcello Demi, Lorenzo Ghiadoni, John Eric Deanfield.   

Abstract

OBJECTIVES: Brachial artery flow-mediated dilation (FMD) is associated with risk factors providing information on cardiovascular prognosis. Despite the large effort to standardize the methodology, the FMD examination is still characterized by problems of reproducibility and reliability that can be partially overcome with the use of automatic systems. We developed real-time software for the assessment of brachial FMD (FMD Studio, Institute of Clinical Physiology, Pisa, Italy) from ultrasound images. The aim of this study is to compare our system with another automatic method (Brachial Analyzer, MIA LLC, IA, USA) which is currently considered as a reference method in FMD assessment.
METHODS: The agreement between systems was assessed as follows. Protocol 1: Mean baseline (Basal), maximal (Max) brachial artery diameter after forearm ischemia and FMD, calculated as maximal percentage diameter increase, have been evaluated in 60 recorded FMD sequences. Protocol 2: Values of diameter and FMD have been evaluated in 618 frames extracted from 12 sequences.
RESULTS: All biases are negligible and standard deviations of the differences are satisfactory (protocol 1: -0.27 ± 0.59%; protocol 2: -0.26 ± 0.61%) for FMD measurements. Analysis times were reduced (-33%) when FMD Studio is used. Rejected examinations due to the poor quality were 2% with the FMD Studio and 5% with the Brachial Analyzer.
CONCLUSIONS: In conclusion, the compared systems show a optimal grade of agreement and they can be used interchangeably. Thus, the use of a system characterized by real-time functionalities could represent a referral method for assessing endothelial function in clinical trials.

Entities:  

Mesh:

Year:  2011        PMID: 20842049     DOI: 10.1097/HJH.0b013e32833fc938

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  Evaluation of endothelial function by flow mediated dilation: methodological issues and clinical importance.

Authors:  Lorenzo Ghiadoni; Massimo Salvetti; Maria Lorenza Muiesan; Stefano Taddei
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-03-12

2.  FloWave.US: validated, open-source, and flexible software for ultrasound blood flow analysis.

Authors:  Crystal L Coolbaugh; Emily C Bush; Charles F Caskey; Bruce M Damon; Theodore F Towse
Journal:  J Appl Physiol (1985)       Date:  2016-08-11

3.  SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.

Authors:  Frank Enseleit; Stephan Michels; Isabella Sudano; Marc Stahel; Sandrine Zweifel; Oliver Schlager; Matthias Becker; Stephan Winnik; Matthias Nägele; Andreas J Flammer; Michel Neidhart; Nicole Graf; Christian M Matter; Burkhardt Seifert; Thomas F Lüscher; Frank Ruschitzka
Journal:  Ophthalmologica       Date:  2017-09-02       Impact factor: 3.250

Review 4.  Intima media thickness, pulse wave velocity, and flow mediated dilation.

Authors:  Rosa Maria Bruno; Elisabetta Bianchini; Francesco Faita; Stefano Taddei; Lorenzo Ghiadoni
Journal:  Cardiovasc Ultrasound       Date:  2014-08-23       Impact factor: 2.062

5.  Tea-induced improvement of endothelial function in humans: No role for epigallocatechin gallate (EGCG).

Authors:  Mario Lorenz; Franziska Rauhut; Christine Hofer; Stefanie Gwosc; Eda Müller; Damaris Praeger; Benno F Zimmermann; Klaus-Dieter Wernecke; Gert Baumann; Karl Stangl; Verena Stangl
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

6.  Total brachial artery reactivity and first time incident coronary heart disease events in a longitudinal cohort study: The multi-ethnic study of atherosclerosis.

Authors:  Joseph F Polak; Pamela Ouyang; Dhananjay Vaidya
Journal:  PLoS One       Date:  2019-04-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.